Skip to main content
TipRanks
Go Ultimate75% OFF

AstraZeneca Pharma India Limited (ASTRAZEN) AI Stock Analysis

44 Followers
IN:ASTRAZEN

AstraZeneca Pharma India Limited

(NSE:ASTRAZEN)

Select Model
Rating:52Neutral
Price Target:INR 6,099.00▲(0.99% Upside)
Action:reiterated
Date:08/28/26

The overall score is heavily pressured by extremely bearish technicals and a stretched valuation. While the balance sheet is solid and income growth is strong, the alarming deterioration in cash flow and gross margins significantly undermines financial quality. The stock's deep downtrend and oversold signals present substantial near-term risk.

Positive Factors
Low LeverageConservative financing gives AstraZeneca Pharma India meaningful resilience if operating conditions weaken. Low leverage limits interest and refinancing pressure, preserves borrowing capacity for strategic needs, and supports continued investment in commercial and medical capabilities.
Negative Factors
Cash Flow WeaknessThe sharp decline in operating and free cash flow weakens internal funding capacity and makes earnings less dependable as a source of liquidity. If this volatility persists, the company may have less flexibility for investment, shareholder returns, or absorbing operational pressures.

AstraZeneca Pharma India Limited (ASTRAZEN) vs. iShares MSCI India ETF (INDA)

-40%-30%-20%-10%0%10%IN:ASTRAZEN-33.08%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 150.79B
Dividend Yield
0.60%
Average Volume (3M)
537
Price to Earnings (P/E)
84.4
Beta (1Y)
0.67
Revenue Growth
29.70%
EPS Growth
-10.76%
Country
India
Employees
760
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

AstraZeneca Pharma India Limited Business Overview & Revenue Model

Company Description

AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company...

AstraZeneca Pharma India Limited Financial Statement Overview

Summary

Strong revenue growth (+13.6%) and net income surge (+62%) are offset by a sharp gross margin contraction (26.5% from 41.6%) and critically weak cash flow generation. Operating cash flow plummeted to INR 68M, covering only 0.7% of debt, raising sustainability concerns.

Income Statement

72Positive

Balance Sheet

86Very Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue26.02B22.76B17.13B12.96B10.03B8.06B
Gross Profit7.85B6.02B7.13B6.22B5.78B4.48B
EBITDA2.62B2.85B1.98B2.36B1.51B1.01B
Net Income1.78B1.88B1.16B1.62B992.90M616.00M
Balance Sheet
Total Assets21.91B19.89B15.18B10.78B9.85B8.57B
Cash, Cash Equivalents and Short-Term Investments5.87B4.49B5.53B5.06B5.00B4.48B
Total Debt962.10M1.11B357.30M45.90M72.10M86.30M
Total Liabilities13.12B11.16B7.48B3.66B3.96B3.45B
Stockholders Equity8.79B8.73B7.70B7.12B5.89B5.11B
Cash Flow
Free Cash Flow032.10M636.10M171.10M497.70M911.80M
Operating Cash Flow068.20M653.60M278.70M582.90M1.01B
Investing Cash Flow0-33.40M308.00M217.40M181.10M47.40M
Financing Cash Flow0-919.00M-655.90M-443.80M-244.80M-94.60M

AstraZeneca Pharma India Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price6039.00

Price Trends

50DMA6362.61Negative
100DMA7150.87Negative
200DMA7807.51Negative

Market Momentum

MACD9.78Negative
RSI39.65Neutral
STOCH32.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Negative. The current price of 6039.00 is below the 20-day moving average (MA) of 6215.44, below the 50-day MA of 6362.61, and below the 200-day MA of 7807.51, indicating a bearish trend. The MACD of 9.78 indicates Negative momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 32.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTRAZEN.

AstraZeneca Pharma India Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ASTRAZEN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:TORNTPHARMIN:TORNTPHARM69NeutralINR 1.77T76.51―0.32%42.06%-3.48%
IN:LUPININ:LUPIN67NeutralINR 905.44B17.38―0.91%24.22%20.24%
IN:GLENMARKIN:GLENMARK66NeutralINR 745.92B51.33―0.19%-0.11%43.72%
IN:SUNPHARMAIN:SUNPHARMA64NeutralINR 4.51T41.14―0.85%12.13%4.94%
IN:DRREDDYIN:DRREDDY62NeutralINR 1.15T41.07―0.58%-3.60%-52.23%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ASTRAZENIN:ASTRAZEN52NeutralINR 150.97B84.44―0.60%29.70%-10.76%

* General Sector Average

Performance Comparison

-20%0%20%40%IN:ASTRAZENIN:DRREDDYIN:GLENMARKIN:LUPININ:SUNPHARMAIN:TORNTPHARMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ASTRAZEN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ASTRAZENAstraZeneca Pharma India Limited6039.00-3052.36-33.57%
IN:DRREDDYDr. Reddy's Laboratories Ltd.1377.00140.3411.35%
IN:GLENMARKGlenmark Pharmaceuticals Limited2643.00779.2541.81%
IN:LUPINLupin Limited1980.00-56.93-2.79%
IN:SUNPHARMASun Pharmaceutical Industries Limited1880.90133.177.62%
IN:TORNTPHARMTorrent Pharmaceuticals Ltd4662.15878.9023.23%

AstraZeneca Pharma India Limited Corporate Events

Delhi High Court Restrains NPPA Action Against AstraZeneca

Nov 2, 2026

AstraZeneca Pharma India Limited operates in the pharmaceutical industry and markets prescription medicines in India, including respiratory inhalation therapies such as Symbicort Turbuhaler. Its portfolio serves healthcare providers and patients in t...

AstraZeneca Pharma India Confirms SEBI Dematerialization Compliance for Q2 FY2026

Oct 26, 2026

AstraZeneca Pharma India Limited has submitted a certificate to BSE and NSE confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate, issued by...

Delhi High Court Grants AstraZeneca India Interim Relief in NPPA Drug Pricing Dispute

Aug 25, 2026

AstraZeneca Pharma India Limited has informed the stock exchanges that the Delhi High Court has granted an interim stay on a National Pharmaceutical Pricing Authority demand notice alleging overcharging on Betaloc-50 tablets. The notice claimed the c...

AstraZeneca Pharma India Discloses Unsolicited ESG Rating from Crisil

Aug 24, 2026

AstraZeneca Pharma India Limited disclosed that Crisil ESG Ratings & Analytics has assigned it an Environmental, Social and Governance score of 57, based solely on publicly available information. The company clarified it did not engage Crisil for thi...

AstraZeneca Pharma India Plans Virtual Meeting With Institutional Investor

Aug 21, 2026

AstraZeneca Pharma India Limited has scheduled a virtual one-on-one meeting with an institutional investor on August 26, 2026, in line with regulatory requirements for disclosure of analyst and investor interactions. The company notes that the date m...

AstraZeneca Pharma India Schedules Virtual Meet with Institutional Investor

Aug 15, 2026

AstraZeneca Pharma India has announced that it will hold a virtual one-on-one meeting with an institutional investor on August 19, 2026, as part of its ongoing engagement with the analyst and investor community. The company noted that the schedule ma...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 28, 2026